InnoCare Pharma Limited (SHA:688428)

InnoCare Pharma Statistics

Total Valuation

InnoCare Pharma has a market cap or net worth of CNY 24.96 billion. The enterprise value is 19.44 billion.

Market Cap	24.96B
Enterprise Value	19.44B

Important Dates

The next estimated earnings date is Friday, November 14, 2025.

Earnings Date	Nov 14, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	268.36M
Shares Outstanding	n/a
Shares Change (YoY)	-3.05%
Shares Change (QoQ)	-32.52%
Owned by Insiders (%)	20.89%
Owned by Institutions (%)	28.55%
Float	1.18B

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	18.90
PB Ratio	3.72
P/TBV Ratio	3.87
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-93.05
EV / Sales	14.65
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-100.78

Financial Position

The company has a current ratio of 7.66, with a Debt / Equity ratio of 0.23.

Current Ratio	7.66
Quick Ratio	7.27
Debt / Equity	0.23
Debt / EBITDA	n/a
Debt / FCF	-7.98
Interest Coverage	-7.49

Financial Efficiency

Return on equity (ROE) is -3.23% and return on invested capital (ROIC) is -2.80%.

Return on Equity (ROE)	-3.23%
Return on Assets (ROA)	-2.48%
Return on Invested Capital (ROIC)	-2.80%
Return on Capital Employed (ROCE)	-4.54%
Revenue Per Employee	1.12M
Profits Per Employee	-177,623
Employee Count	939
Asset Turnover	0.14
Inventory Turnover	1.31

Taxes

In the past 12 months, InnoCare Pharma has paid 5.29 million in taxes.

Income Tax	5.29M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +65.27% in the last 52 weeks. The beta is 0.93, so InnoCare Pharma's price volatility has been similar to the market average.

Beta (5Y)	0.93
52-Week Price Change	+65.27%
50-Day Moving Average	27.52
200-Day Moving Average	21.94
Relative Strength Index (RSI)	33.17
Average Volume (20 Days)	9,212,020

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, InnoCare Pharma had revenue of CNY 1.32 billion and -208.88 million in losses. Loss per share was -0.13.

Revenue	1.32B
Gross Profit	1.17B
Operating Income	-378.39M
Pretax Income	-215.25M
Net Income	-208.88M
EBITDA	-304.10M
EBIT	-378.39M
Loss Per Share	-0.13

Balance Sheet

The company has 7.06 billion in cash and 1.54 billion in debt, giving a net cash position of 5.52 billion.

Cash & Cash Equivalents	7.06B
Total Debt	1.54B
Net Cash	5.52B
Net Cash Per Share	n/a
Equity (Book Value)	6.72B
Book Value Per Share	5.53
Working Capital	6.82B

Cash Flow

In the last 12 months, operating cash flow was -144.84 million and capital expenditures -48.02 million, giving a free cash flow of -192.86 million.

Operating Cash Flow	-144.84M
Capital Expenditures	-48.02M
Free Cash Flow	-192.86M
FCF Per Share	n/a

Margins

Gross margin is 88.27%, with operating and profit margins of -28.64% and -15.81%.

Gross Margin	88.27%
Operating Margin	-28.64%
Pretax Margin	-16.29%
Profit Margin	-15.81%
EBITDA Margin	-23.02%
EBIT Margin	-28.64%
FCF Margin	n/a

Dividends & Yields

InnoCare Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	3.05%
Shareholder Yield	3.05%
Earnings Yield	-0.84%
FCF Yield	-0.77%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

InnoCare Pharma has an Altman Z-Score of 3.26 and a Piotroski F-Score of 4.

Altman Z-Score	3.26
Piotroski F-Score	4